Publications
Chosen filters:
Chosen filters:
Notch induces T cell receptor gamma delta thymocytes to differentiate along a bipotent CD4 CD8 double positive pathway Ghent University
CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor Institute of Tropical Medicine
Immunosuppressive effects of a CD4 receptor down-modulator: in vitro study of the signal peptide-dependent ER translocation inhibitor cyclotriazadisulfonamide (CADA) KU Leuven
The small molecule cyclotriazadisulfonamide (CADA) was identified as an inhibitor of human immunodeficiency virus replication. It was shown that its antiviral potency is due to signal peptide-dependent inhibition of co-translational translocation of human CD4, the primary receptor for human immunodeficiency virus entry. The CD4 receptor plays an important role in the immune system, especially during activation of T cells by stabilizing the ...
CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor KU Leuven
The cyclotriazadisulfonamide (CADA) compounds are a new class of specific CD4-targeted HIV entry inhibitors. The in vitro anti-HIV activity of CADA was shown to correlate with its ability to specifically downmodulate cell surface expression of the CD4 receptor in human cells. Here, we evaluated its potential as an anti-HIV microbicide. CADA exerted a clear CD4 receptor downregulating effect in dendritic cells (DC) and subsequently inhibited ...
Unsymmetrical cyclotriazadisulfonamide (CADA) compounds as human CD4 receptor down-modulating agents KU Leuven
Cyclotriazadisulfonamide (CADA) inhibits HIV at submicromolar levels by specifically down-modulating cell-surface and intracellular CD4. The specific biomolecular target of CADA compounds is unknown, but previous studies led to an unsymmetrical binding model. To test this model, methods were developed for effective synthesis of diverse, unsymmetrical CADA compounds. A total of 13 new, unsymmetrical target compounds were synthesized, as well as ...